ScreenerHero

VCELVericel Corporation

NAS · US · Healthcare · Biotechnology · vcel.com
42.68USD-2.04%Mkt Cap: 2.19B $P/E: 87.10

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap2.19B $
Enterprise Value2.09B $
Revenue (TTM)306.30M $
Gross Profit205.60M $
Net Income (TTM)16.52M $
Revenue/Share6.037 USD
Last Price42.68 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees398
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS92346J1088
Valuation
P/E (Trailing)87.10
P/E (Forward)49.78
PEG—
EV/EBITDA66.99
EV/Revenue6.81
P/S7.04
P/B5.82
EPS (TTM)0.46
EPS (Forward)0.85
52W Range
28.9567% of range49.32
52W High49.32 USD
52W Low28.95 USD
Profitability
Gross Margin74.42%
Oper. Margin0.56%
EBITDA Margin10.17%
Profit Margin5.98%
ROE4.66%
ROA3.39%
Growth
Revenue Growth22.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF51.91M $
CapEx (TTM)27.16M $
FCF Margin18.13%
FCF Yield2.54%
Net Debt-69.33M $
Net Debt/EBITDA-2.23
Balance Sheet
Debt/Equity0.27
Current Ratio5.04
Quick Ratio4.53
Book Value/Sh7.231 USD
Cash/Share3.173 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateOct 16, 2013
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)60.57 USD
Upside (mean)+41.9%
Target Range55.00 USD – 72.00 USD
$55.00+41.9% to mean$72.00
# Analysts7
Ownership
Shares Out.51.21M
Float50.58M
Insiders1.19%
Institutions111.13%
Short Interest
Short Ratio8.3d
Short % Float11.15%
Short % Out.8.66%
Shares Short4.43M
Short (prev mo.)4.91M
Technical
SMA 5044.30 (-3.7%)
SMA 20038.02 (+12.3%)
Beta1.07
S&P 52W Chg18.16%
Avg Vol (30d)456.35K
Avg Vol (10d)442.43K
Technical Indicators
RSI (14)38.9
MACD-0.2518
MACD Signal0.1861
MACD Hist.-0.4379
BB Upper47.51 USD
BB Middle45.08 USD
BB Lower42.64 USD
BB Width10.82%
ATR (14)1.684 USD
Vol Ratio (20d)1.29x